[go: up one dir, main page]

HN2006014095A - Forma cristalina ortorrombica del maleato de asenapina - Google Patents

Forma cristalina ortorrombica del maleato de asenapina

Info

Publication number
HN2006014095A
HN2006014095A HN2006014095A HN2006014095A HN2006014095A HN 2006014095 A HN2006014095 A HN 2006014095A HN 2006014095 A HN2006014095 A HN 2006014095A HN 2006014095 A HN2006014095 A HN 2006014095A HN 2006014095 A HN2006014095 A HN 2006014095A
Authority
HN
Honduras
Prior art keywords
orthromby
crystal form
asenapine maleate
asenapine
maleate
Prior art date
Application number
HN2006014095A
Other languages
English (en)
Inventor
Johannes Heeres Gerardus
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2006014095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon Nv filed Critical Organon Nv
Publication of HN2006014095A publication Critical patent/HN2006014095A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invencion se refiere a una nueva forma cristalina de asenapina, a metodos para su preparacion y a composiciones farmaceuticas que comprenden dicha forma cristalina.
HN2006014095A 2005-04-07 2006-04-06 Forma cristalina ortorrombica del maleato de asenapina HN2006014095A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102742 2005-04-07
EP05102969 2005-04-14

Publications (1)

Publication Number Publication Date
HN2006014095A true HN2006014095A (es) 2010-08-19

Family

ID=36617328

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2006014095A HN2006014095A (es) 2005-04-07 2006-04-06 Forma cristalina ortorrombica del maleato de asenapina

Country Status (31)

Country Link
EP (2) EP1917267B1 (es)
JP (1) JP5058151B2 (es)
KR (1) KR101422843B1 (es)
AR (1) AR056306A1 (es)
AT (2) ATE418556T1 (es)
AU (1) AU2006231617B2 (es)
BR (1) BRPI0609741A8 (es)
CA (1) CA2603509C (es)
CY (2) CY1106902T1 (es)
DE (2) DE602006004463D1 (es)
DK (2) DK1710245T3 (es)
DO (1) DOP2006000082A (es)
ES (2) ES2318742T3 (es)
GT (1) GT200600135A (es)
HN (1) HN2006014095A (es)
HR (1) HRP20070429T3 (es)
IL (1) IL186355A (es)
MX (1) MX2007012445A (es)
MY (1) MY137969A (es)
NO (1) NO340520B1 (es)
NZ (1) NZ562124A (es)
PE (1) PE20061311A1 (es)
PL (2) PL1710245T3 (es)
PT (2) PT1917267E (es)
RS (1) RS50532B (es)
RU (1) RU2405786C2 (es)
SI (2) SI1917267T1 (es)
SV (1) SV2006002473A (es)
TW (1) TWI364423B (es)
UY (1) UY29459A1 (es)
WO (1) WO2006106135A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078024A1 (en) * 2006-10-06 2009-07-15 N.V. Organon Amorphous asenapine and processes for preparing same
CA2766291C (en) * 2009-06-24 2016-06-21 Msd Oss B.V. Injectable formulations containing asenapine and method of treatment using same
US8779161B2 (en) 2010-06-18 2014-07-15 Dr. Reddy's Laboratories Limited Asenapine maleate
WO2012066565A2 (en) * 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
ITMI20110734A1 (it) * 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
EP2524921A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
EP2524920A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Asenapine Hydrochloride Salt Forms
JP6014656B2 (ja) * 2011-05-18 2016-10-25 ラビラトリオス レスビ エス エレ 化合物の多形体
EP2709615A1 (en) 2011-05-18 2014-03-26 Laboratorios Lesvi, S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
CN104487071B (zh) * 2012-07-26 2017-06-13 久光制药株式会社 贴附剂
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
WO2014090386A1 (en) 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
US10786520B2 (en) 2015-09-02 2020-09-29 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2018115001A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2019243452A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
DE69502939T2 (de) * 1994-03-02 1998-10-22 Akzo Nobel Nv Sublinguales oder bukkales arzneimittel
AU2418499A (en) * 1997-12-19 1999-07-12 Akzo Nobel N.V. Org-5222 in the treatment of depression
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight

Also Published As

Publication number Publication date
CY1108742T1 (el) 2014-04-09
CY1106902T1 (el) 2012-09-26
TW200722428A (en) 2007-06-16
EP1710245B1 (en) 2007-08-22
CA2603509C (en) 2013-12-03
TWI364423B (en) 2012-05-21
DE602006004463D1 (de) 2009-02-05
PT1710245E (pt) 2007-10-03
PE20061311A1 (es) 2007-02-09
MY137969A (en) 2009-04-30
IL186355A (en) 2016-05-31
ES2318742T3 (es) 2009-05-01
DOP2006000082A (es) 2006-11-30
MX2007012445A (es) 2007-11-07
RU2405786C2 (ru) 2010-12-10
PT1917267E (pt) 2009-02-04
UY29459A1 (es) 2006-11-30
KR20080005253A (ko) 2008-01-10
AR056306A1 (es) 2007-10-03
DK1917267T3 (da) 2009-04-14
ES2293626T3 (es) 2008-03-16
BRPI0609741A2 (pt) 2010-04-27
EP1710245A1 (en) 2006-10-11
DK1710245T3 (da) 2007-12-03
PL1710245T3 (pl) 2008-01-31
NO340520B1 (no) 2017-05-02
SI1710245T1 (sl) 2007-12-31
CA2603509A1 (en) 2006-10-12
SV2006002473A (es) 2009-11-24
WO2006106135A1 (en) 2006-10-12
DE602006000080T2 (de) 2008-05-15
AU2006231617A1 (en) 2006-10-12
RS50532B (sr) 2010-05-07
EP1917267B1 (en) 2008-12-24
IL186355A0 (en) 2008-01-20
BRPI0609741A8 (pt) 2018-03-13
KR101422843B1 (ko) 2014-07-24
AU2006231617B2 (en) 2010-06-03
JP5058151B2 (ja) 2012-10-24
GT200600135A (es) 2006-11-07
SI1917267T1 (sl) 2009-04-30
EP1917267A1 (en) 2008-05-07
HRP20070429T3 (en) 2007-11-30
NZ562124A (en) 2010-07-30
JP2008534656A (ja) 2008-08-28
ATE418556T1 (de) 2009-01-15
ATE370954T1 (de) 2007-09-15
PL1917267T3 (pl) 2009-06-30
RU2007141198A (ru) 2009-05-20
NO20075142L (no) 2007-11-05
DE602006000080D1 (de) 2007-10-04

Similar Documents

Publication Publication Date Title
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
NO20091395L (no) Nye tiofenderivater
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
NO20082793L (no) Nye tiofenderivater
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
EA201200506A1 (ru) СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ)БЕНЗОЛА
UY31484A1 (es) Piperidinas heteroaril-sustituidas
HN2008001191A (es) Compuestos de biciclolactama sustituida
ECSP10010295A (es) Formulacion de anticuerpo
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
DOP2012000150A (es) Triazolopiridinas
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
CR9723A (es) Nueva forma cristalina de un derivado de piridazino[4,5-b] indol
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CL2008000585A1 (es) Compuestos derivados de nicotinamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada por prostaglandina d2 producida por h-pgds.
CL2013000734A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.
ATE465719T1 (de) Oral zerfallende zusammensetzung von olanzapin oder donepezil
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BRPI0514833A (pt) fenilaminotiazóis substituìdos e seu uso
CR11078A (es) Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada